StreetAlpha.app
Home › Stocks › PRLD

Prelude Therapeutics Inc (PRLD)

Healthcare
$3.23
▼ −0.77%
LAST CLOSE · NOV 20

Prelude Therapeutics develops precision cancer medicines, including targeted protein degraders and antibody drug conjugates, for patients with underserved cancers. It last closed at $3.23 on Nov 20, down 0.77% on the day. The next earnings report for PRLD is expected around Tue, Mar 9, 2027. For the quarter ended Sep 2026, PRLD reported EPS of -$0.12 on revenue of $5.6M, with revenue down 13.1% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months PRLD insiders bought $25.0M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is PRLD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PRLD.

Key Stats

Last 12 months
Results
Revenue
$21.6M
+105.4% vs a year ago
Net income
−$53.3M
−247.1% margin
EPS (diluted)
−$0.59
Free cash flow
−$28.0M
−129.6% margin
Valuation
Market cap
$258.6M
80.1M shares
P/E
–
No P/E while losing money
Price to sales
12.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$23.4M
At Sep 30
Shareholder equity
$124.1M
Shares outstanding
80.1M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $7.0M$7.0MFY2024FY2025: $12.1M$12.1MFY2025

From PRLD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 9
Estimated date · Time not announced
Reported EPS
-$0.12
Quarter ended Sep 2026
Year ago EPS
-$0.26
Same quarter last year
Revenue
$5.6M
−13.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.38Dec '24Mar 2025: -$0.42Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.26Sep '25Dec 2025: -$0.20Dec '25Mar 2026: -$0.13Mar '26Jun 2026: -$0.14Jun '26Sep 2026: -$0.12Sep '26Latest -$0.12
Revenue by quarter
Dec 2024: $4.0MDec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $6.5MSep '25Dec 2025: $5.6MDec '25Mar 2026: $4.6MMar '26Jun 2026: $5.7MJun '26Sep 2026: $5.6MSep '26Latest $5.6M
How PRLD moved after its last 8 reports
Average move the session after a report ±7.1%
Nov 16, 2026Time not announced−1.2%
Aug 11, 2026Time not announced+10.1%
May 12, 2026Time not announced−3.3%
Mar 10, 2026Time not announced+16.5%
Nov 12, 2025Time not announced+8.9%
Aug 14, 2025Time not announced+4.2%
May 6, 2025After the close−4.0%
Mar 10, 2025Time not announced−9.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PRLDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PRLD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PRLD

Technical Analysis

PRLD · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 14% below its 20 day and 19% below its 50 day average. It is 28% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Oct 16) at $3.18, and the nearest resistance the Pivot R1 at $3.30.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.6%/day
Key levels
$6.8352 week high+111.5%
$4.44100 day average+37.5%
$4.13200 day average+27.9%
$3.8350 day average+18.6%
$3.78Swing high (Oct 21)+17.0%
$3.6720 day average+13.6%
$3.30Pivot R1+2.2%
$3.23Pivot+0.0%
$3.23Last close
$3.18Swing low (Oct 16)−1.5%
$3.17Pivot S1−1.9%
$1.2952 week low−60.1%
Indicators
RSI (14)35.46Weak, oversold below 30Neutral
MACD-0.17Below its signal lineBearish
Stochastic5.0Near the bottom of its rangeOversold
ADX (14)16.1No clear trend
Williams %R-93.9Oversold below −80, overbought above −20Oversold
CCI (20)-127.4Oversold below −100, overbought above 100Oversold
Rate of change−10.3%Change over 10 sessionsBearish
ATR (14)$0.28Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PRLD

What happened before

See how PRLD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PRLD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PRLD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PRLDHow many large options trades hit PRLD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PRLD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲52 buying vs 30 selling
  • ▲Held by funds +3.2 pts
  • ▲Funds holding +17
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9275+22.7%
In funds' top 1000–
Held by funds65.1%61.9%+3.2 pts
New / increased23 / 2934 / 25−11.9%
Reduced / sold out24 / 68 / 13+42.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRLD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PRLD Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$25.0M2 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $25.0M between Apr 21 and Apr 21.
2026-04 bought $25.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Apr 21Orbimed Advisors LLCDirectorBuy2,815,315$4.44$12.5M
Apr 21David P BonitaDirectorBuy2,815,315$4.44$12.5M
Mar 25, 2025Krishna VaddiCEOBuy675,000$0.69$466K
Mar 25, 2025Andrew CombsChief Chemistry OfficerBuy100,000$0.69$69K
Mar 21, 2025Krishna VaddiCEOBuy20,416$0.73$15K
Mar 17, 2025Krishna VaddiCEOBuy39,105$0.75$29K
Every insider buy and sale for PRLD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PRLD insider trades →

From SEC Form 4 filings by PRLD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRLD is in one of them and how their past PRLD trades turned out.

PRLD in the AI portfolios
Loading…

PRLD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRLD in an article yet. Here's the latest on the wider market.

PRLD in the news

About Prelude Therapeutics

Prelude Therapeutics is a precision oncology company based in Wilmington, Delaware. It discovers and develops cancer medicines, including small molecule inhibitors, protein degraders, and antibody drug conjugates, aimed at cancers with limited treatment options. Its pipeline targets driver mutations in blood cancers and solid tumors, such as a JAK2V617F inhibitor for myeloproliferative neoplasms and a KAT6A degrader for advanced breast cancer. The company serves cancer patients and is advancing its candidates through clinical trials.

Headquarters
Wilmington, DE